CAMBRIDGE, England and WALTHAM, Mass., July 12,
2023 /PRNewswire/ -- Abcam plc ("Abcam,"
"Company," "Group") (Nasdaq: ABCM), a global leader in the supply
of life science research tools, today held an Extraordinary General
Meeting of its shareholders (the "EGM") that was convened following
a requisition notice from Dr. Jonathan
Milner dated May 30, 2023 (the
"Requisition Notice").
As previously announced, on June 28,
2023, the Company received a letter of undertaking from Dr.
Milner withdrawing the Requisition Notice and therefore the
resolutions that Dr. Milner had previously proposed were formally
withdrawn at the EGM, in accordance with English law, and were not
put to a vote.
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
antibodies, assays, and other research tools to address important
targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health.
Abcam's worldwide customer base of approximately 750,000 life
science researchers' uses Abcam's antibodies, reagents, biomarkers,
and assays. By actively listening to and collaborating with these
researchers, the Company continuously advances its portfolio to
address their needs. A transparent program of customer reviews and
datasheets, combined with industry-leading validation initiatives,
gives researchers increased confidence in their results.
Founded in 1998 and headquartered in Cambridge, UK, the Company has served
customers in more than 130 countries. Abcam's American Depositary
Shares (ADSs) trade on the Nasdaq Global Select Market (Nasdaq:
ABCM).
For more information, please visit www.abcam.com or
www.abcamplc.com
Abcam plc
Tommy Thomas, CPA
Vice President, Investor Relations
+1 617-577-4205
tommy.thomas@abcam.com
152 Grove Street, Building 1100
Waltham, MA 02453
Media enquiries
US: Joele Frank
+1 212-355-4449
Abcam-JF@joelefrank.com
UK and Europe: FTI
+44 (0)20-3727-1000
Abcam@fticonsulting.com
Logo -
https://mma.prnewswire.com/media/1670705/Abcam_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/abcam-plc--all-resolutions-withdrawn-at-abcams-egm-301875537.html
SOURCE Abcam PLC
